Products

What will AGI do for Benzphetamine?

This classification denotes a cns stimulant and anorexiant with the molecular formula C17H21N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0M3S43XK27, chemically known as (r,s)-n-benzyl-alpha,n-dimethylphenethylamin but more generally known as benzfetamine, which bears US NIH Compound Identifier 2341. European Medicines Agency schedules Benzfetamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05748MIG. The term BENZPHETAMINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 19 1975, List 5). BENZFETAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. As of Q4 2014, BENZPHETAMINE remains US FDA's Preferred Term for this commodity. Benzphetamine bears US NLM identifiers UMLS ID C0005096 and NCI Concept Code C61647. SMILES: CC(CC1=CC=CC=C1)N(C)CC2=CC=CC=C2.

How AGI delivers it

Four ways AGI delivers for Benzphetamine

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Benzphetamine, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Benzphetamine, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Benzphetamine connects

measured by

  • Active Ingredient Assaymodel
  • Assay Puritymodel
  • Chiral Enantiomeric Excessmodel
  • Content Uniformitymodel
  • Residual Solventmodel
  • Tablet Dissolution Ratemodel